Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merrimack Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MACK
Nasdaq
8731
http://www.merrimackpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merrimack Pharmaceuticals Inc
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
- Apr 9th, 2018 5:30 am
Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications
- Apr 4th, 2018 6:15 am
Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer
- Mar 14th, 2018 5:30 am
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
- Mar 13th, 2018 7:45 am
Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT
- Mar 12th, 2018 5:06 pm
Merrimack Pharmaceuticals, Inc. to Host Earnings Call
- Mar 12th, 2018 5:30 am
Merrimack Provides Business Update and Reports 2017 Financial Results
- Mar 12th, 2018 4:27 am
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
- Mar 12th, 2018 4:25 am
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
- Mar 5th, 2018 5:00 am
Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)?
- Feb 27th, 2018 3:11 am
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
- Feb 26th, 2018 4:55 am
What's in the Cards for Merrimack (MACK) in Q4 Earnings?
- Feb 23rd, 2018 7:10 am
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
- Feb 20th, 2018 5:00 am
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
- Feb 15th, 2018 5:00 am
New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
- Feb 6th, 2018 6:25 am
Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2018 6:00 am
Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
- Dec 11th, 2017 2:12 am
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
- Nov 30th, 2017 4:50 am
With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?
- Nov 20th, 2017 6:04 pm
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
- Nov 14th, 2017 5:00 am
Scroll